SummitTX Capital’s Amedisys AMED Stock Holding History

SummitTX Capital’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-3,600	Closed	-$333K	–	732
2025 Q1	$333K	Buy	+3,600	New	+$332K	0.01%	639

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

SummitTX Capital's AMED Position: Q2 2025 in Review

SummitTX Capital sold out of Amedisys (AMED) in Q2 2025, closing a stake of 3,600 shares — an estimated $333K sold.

SummitTX Capital first reported a position in AMED in Q1 2025 and held it in 1 quarter. The position peaked at $333K in Q1 2025. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

SummitTX Capital reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
SummitTX Capital sold 3,600 Amedisys shares in Q2 2025, an estimated $333K.
SummitTX Capital first reported a position in Amedisys in Q1 2025 and held it in 1 quarter.
SummitTX Capital's Amedisys position peaked at $333K in Q1 2025.
319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on SummitTX Capital's 13F filing for Q2 2025, filed 14 Aug 2025.